Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer`s Disease


Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer`s Disease




The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer`s disease over a treatment period of a minimum of 104-weeks. In addition patients will be seen for safety visits at 4 and 12 weeks post treatment.

Study Status: Terminated


Condition Intervention Phase
Alzheimer`s Disease Drug: Avagacestat
Drug: Placebo
Phase 2

Verified by Bristol-Myers Squibb September, 2013

Sponsored by: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb identifier: NCT00890890

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic Lou Ruvo Center For Brain Health
Las Vegas, Nevada 89106
United States

Bristol-Myers Squibb., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site